Achillion reports interim results on ACH-3102 Achillion announced that it has completed enrollment in a pilot Phase 2a trial evaluating ACH-3102, a second-generation pan-genotypic NS5A inhibitor, in combination with ribavirin for the treatment of patients with chronic genotype 1b hepatitis C virus infection. Up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.
Achillion sees FY14 EPS to approach (70c), consensus (81c) The company expects that research and development expenses during 2014 will be approximately $55M-60M and that net cash used in operating activities in 2014 will be approximately $60M-65M based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs.